Predict your next investment

Corporation
HEALTHCARE | Drug Development
themedicinescompany.com

See what CB Insights has to offer

Executives

21

Board of Directors

1

The Medicines Company Board of Director

1 Board of directors

The Medicines Company has 1 board of directors, including Glenn Sblendorio.

Name

Firm

Work History

Other Seats

Glenn Sblendorio

Glenn Sblendorio, M.B.A., is President and Chief Executive Officer of IVERIC bio (previously Ophthotech Corporation). He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. Mr. Sblendorio also served as a member of the Board of Directors of Ophthotech from 2013 to 2016. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BBA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

The Medicines Company

Name

Glenn Sblendorio

Firm

Work History

Glenn Sblendorio, M.B.A., is President and Chief Executive Officer of IVERIC bio (previously Ophthotech Corporation). He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. Mr. Sblendorio also served as a member of the Board of Directors of Ophthotech from 2013 to 2016. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BBA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

Other Seats

The Medicines Company

The Medicines Company Management Team

21 Team Members

The Medicines Company has 21 executives. The Medicines Company's founder is Scott Johnson. The Medicines Company's current Senior Vice President is Chris Visioli.

Name

Work History

Title

Status

Chris Visioli

Senior Vice President

Current

John M Nystrom

Chief Technology Officer

Current

Scott Johnson

JSB Partners, and MPM Capital

Founder

Former

Mark Timney

Purdue Pharma, MSD, Merck & Co., and Prudential

Chief Executive Officer

Former

John Kelley

Phyxius Pharma, Aventis, and Marion Merrell Dow

President, Chief Operating Officer

Former

Name

Chris Visioli

John M Nystrom

Scott Johnson

Mark Timney

John Kelley

Work History

JSB Partners, and MPM Capital

Purdue Pharma, MSD, Merck & Co., and Prudential

Phyxius Pharma, Aventis, and Marion Merrell Dow

Title

Senior Vice President

Chief Technology Officer

Founder

Chief Executive Officer

President, Chief Operating Officer

Status

Current

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.